Clinical Trial EnrollmentManagement believes that adding fludarabine will improve enrollment in their ongoing trials.
Financial StabilityNkarta has $352M cash and recent restructuring extends runway into 2029, ensuring the company is fully funded well past initial POC readouts across several autoimmune indications.
Strategic DecisionNkarta made the right strategic decision in adding fludarabine to the lymphodepletion regimen for their autoimmune disease development, which improves the setup for NKX019’s first clinical read-out.